meclocycline

Trade name: declomycin

Small moleculeapproved

Meclocycline is a tetracycline antibiotic. It is used topically for skin infections treatment. Tetracyclines are broad-spectrum bacteriostatic agents and act by inhibiting protein synthesis by blocking the binding of aminoacyl tRNA (transfer RNA) to the mRNA (messenger RNA) ribosome complex. Meclocycline might increase sensitivity to light when it is used with Aminolevulinic acid. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2006 (NCT00385515)

Timeline

1960s

Nov 14, 1960
Lederle — First NDA Organization
Nov 14, 1960
Lederle — NDA Organization

2000s

Jan 1, 2006
Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Acne Vulgaris (approved 1981)

Studied for

Stomatitis · Phase 2

Mechanism of action

Bacterial 70S ribosomeINHIBITOR
Bacterial 70S ribosome inhibitor
16s RRNA

Approval history

approved—

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O

Mol. weight: 476.864 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Availability: Discontinued

Oral

Parenteral

Topical

Sources

Also known as

7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide
gs 2989
meclan
meclan
meclan
meclan
meclan
meclan
meclocil
meclocycline
meclocycline
meclocycline
meclocycline
meclocycline
meclocycline
meclocycline
meclocycline monohydrochloride, (4s-(4alpha,4aalpha,5alpha,5aalpha,12aalpha))-isomer
meclocycline sulfosalicylate
meclocycline sulfosalicylate
meclocycline sulfosalicylate
meclocycline sulfosalicylate
meclocycline sulfosalicylate
meclocycline sulfosalicylate
mecloderm
mecloderm
meclosorb
meclosorb
meclosorb
quoderm
samil
traumatociclina

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00385515	Phase 2	Jun 1, 2006	Mucosal Therapeutics

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Mucosal Therapeutics	For profit	1	1	1	2006

1 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
Johnson and Johnson	For profit	NDA2	—
Lederle	For profit	NDA	Nov 14, 1960